Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of respiratory disease
3.2.1.2 Growing demand for OTC medications
3.2.1.3 Rising geriatric population
3.2.1.4 Increasing awareness among people about respiratory conditions
3.2.2 Industry pitfalls & challenges
3.2.2.1 Strict government and regulatory guidelines
3.3 Growth potential analysis
3.4 Pipeline analysis
3.5 Regulatory landscape
3.6 Porter’s analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive positioning matrix
4.5 Strategic dashboard
Chapter 5 Market Estimates and Forecast, By Drug Type, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Secretion enhancer
5.2.1 Potassium citrate
5.2.2 Potassium iodide
5.2.3 Sodium citrate
5.2.4 Guaiphenesin
5.2.5 Ammonium chloride
5.2.6 Other secretion enhancer
5.3 Mucolytics
5.3.1 Bromhexine
5.3.2 Ambroxol
5.3.3 Acetyl cysteine
5.3.4 Carbocisteineurine
Chapter 6 Market Estimates and Forecast, By Dosage Form, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Oral solids
6.2.1 Powder & granules
6.2.2 Tablet
6.2.3 Capsule
6.3 Oral liquids
6.3.1 Syrup
6.3.2 Solution
6.3.3 Suspension
6.4 Inhalants
Chapter 7 Market Estimates and Forecast, By Medication, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Prescription drugs
7.3 Over-the-counter drugs
Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 Hospital pharmacies
8.3 Retail store & drug store
8.4 Online pharmacies
Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
9.1 Key trends, by region
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Rest of Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Rest of Latin America
9.6 Middle East and Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 Rest of Middle East and Africa
Chapter 10 Company Profiles
10.1 Abbott Laboratories
10.2 AstraZeneca
10.3 Cipla Inc.
10.4 Genexa Inc.
10.5 GlaxoSmithKline (GSK) plc
10.6 Merck KGaA
10.7 Perrigo Company plc
10.8 Reckitt Benckiser Group PLC
10.9 Sanofi
10.10 Sun Pharmaceutical Industries Ltd.
10.11 The Himalaya Drug Company
